The big-pharma companies are increasingly outsourcing their production of drugs to contract manufacturing organizations (CMOs) solely to reduce cost of production, working capital requirement, and time-to-market, or to obtain a specific expertise not available in-house. The biggest factor to drive the growth of CMOs in the pharmaceutical industry is the growing need of state-of-the-art process & production technologies, which have proven highly effective in meeting regulatory requirements.

The global market for bio-pharma has grown at a CAGR of 11.2% over the last few years. The share of the CMO market of the total bio-pharma market has also increased over 2001 to -2008. The Bio-Pharma CMO market can be segmented into Mammalian CMO market and Microbial CMO market. The largest capacity share of the bio-pharma CMO market is held by the Mammalian CMO market.

The main growth driver of the bio-pharma CMO market is the increasing outsourcing trend among the bio-pharma manufacturers as a result of stringent regulatory environment. However, factors like global economic crisis, intellectual property risk, increasing regulatory cost, and lack of integrated CMOs are also acting as a roadblock in the path of overall industry growth, which are highly recommended to be solved to grow in the long term.

The current report analyzes the global bio-pharma CMO market. The various drivers, opportunities and the challenges faced by the market are discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.


Scope
The current report analyzes the bio-pharma CMO market. The various drivers, opportunities and the challenges faced by the market are discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
[Studien Infos ausblenden]

Table of Contents

1. Overview

1.1 Global Pharmaceutical Market

Market Size
Breakdown by Region

1.2 Global Bio-Pharmaceutical Market

Market Size
Breakdown by Segments


1.3 Global Contract Outsourcing Market

Market Size
Value Chain

2. Global CMO Bio-Pharma Market

2.1 Overview
2.2 Market Size

2.3 Segmentation

2.3.1 Mammalian CMO Market
2.3.2 Microbial CMO Market

3. India- Outsourcing Hub

3.1 Overview

3.2 India’s Advantage

3.2.1 Cost Efficiency Attractiveness
3.2.2 Skilled Manpower
3.2.3 USFDA approved plants
3.2.4 Vertical Integration

3.3 Key Issues

3.3.1 IP Risk Perception Limiting Growth
3.3.2 Regulatory Environment
3.3.3 High Tax Rates

4. Market Movements

4.1 Key Trends

4.1.1 Trends in Outsourcing to Asia
4.1.2 Growing Share of Bio-Pharma market
4.1.3 Declining Internal Manufacturing Capacity

4.2 Growth Drivers

4.2.1 Growing World Population
4.2.2 Bio-Pharma Companies facing Cost cutting pressures
4.2.3 Growth in Asia/Africa/Australia markets
4.2.4 Growing Generics Market

4.3 Challenges

4.3.1 Weakening of Outsourcing Trend
4.3.2 Intellectual Property Risk
4.3.3 Increasing Regulatory Costs
4.3.4 Lack of Integrated CMOs

5. Competitive Landscape

5.1 Industry-wide Bio-Pharma Capacity Distribution
5.2 Cell Culture Bioreactor Capacity Distribution

6. Company Profiles

6.1 Lonza

Overview
Key Financials
Business Strategies
Re-Engineering Lonza
Focus on Increasing Capacity in Bio-Pharma

6.2 Jubilant Organosys

Overview
Key Financials
Business Strategies
Integrated Business Model
Increasing Organizational Efficiencies

6.3 Piramal Healthcare

Overview
Key Financials
Business Strategies
Acquisition Led Growth Strategy
Increasing Focus on Custom Manufacturing

6.4 Patheon Inc.

Overview
Key Financials
Business Strategies
Focus on Operational Efficiency
Increasing Market Share

7. Market Outlook

7.1 Market Forecast

7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis
[Inhaltsverzeichnis ausblenden]

List of Tables

Dependent & Independent Variables, 2001– 2009
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

List of Figures

Global Pharmaceutical Market, 2003-2008
Global Pharmaceutical Market by Region, 2008
Global Bio-Pharmaceutical Market, 2002-2008
Bio-Pharmaceutical Commercial Product Sales, 2002-2008
Global Pharmaceutical Contract Outsourcing Market, 2007-2008
Utilization of Outsourcing across Value Chain
Global CMO Bio-Pharma Market Size, 2000-2009
Segmentation of Bio-Pharma CMO Market
Mammalian Cell Culture Capacity, 2006-2009E
Microbial CMO Market by Capacity (Fermenter Volume), 2003-2009E
Indian Custom Manufacturing Outsourcing Market, 2007-2010E
Cost Efficiency Attractiveness in India
Skilled Manpower Attractiveness in India
No. of USFDA Approved Plants Comparison
Regulatory Environment Attractiveness in India
Comparison of Corporate Income Tax Rates by Country
Trend in Outsourcing to Asia, 2009
Bio-Pharma CMO Market Share, 2001 & 2008
Declining Internal Custom Manufacturing Capacity
World Population, 2000-2009
Pharma Market Potential Growth by Region, 2009-2013
Global Generic Market, 2008-2014
Global Bio-Pharma Industry Capacity Distribution, 2009
CMO & PDC Cell Culture Bioreactor Capacity distribution, 2004-2008
Lonza Business Revenues, 2005-2009
Jubilant Organosys Business Revenues, 2005-2009
Piramal Healthcare Business Revenues, 2005-2009
Patheon Business Revenues, 2005-2009
Global Bio-Pharma CMO Market Forecast, 2009-2013F
[Tabellenverzeichnis ausblenden]